Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether long-term treatment with a beta-blocker
(BB) such as atenolol and/or an angiotensin receptor blocker (ARB) such as telmisartan, given
to adult patients with bicuspid aortic valve (BAV) disease (aortopathy) reduces the widening
(dilatation) of the aorta from its baseline size.